June 9 2011 – Ascend Trial – Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PIPF-016 (ASCEND) is a Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. The study objectives are to confirm the treatment effect of pirfenidone compared with placebo on change in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF), and to confirm the…

Brief Summary

Official Title: “A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)”

For Additional Information on Officials/ Investigators, Please go towww. ASCENDTrial.com Study Chair InterMune

You can read the entire article at:

http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01366209

This entry was posted in Uncategorized. Bookmark the permalink.

3 Responses to June 9 2011 – Ascend Trial – Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  1. Chelsea says:

    Pulm Med. 2011;2011:240805. Epub 2011 Apr 7.

    Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: an open pilot study
    http://www.ncbi.nlm.nih.gov/pubmed/21660226

  2. This is an excellent posting, I was wondering basically can use this kind of write-up on my web site, I am going to website link that returning to your site although. If this is an issue make sure you inform me and i also will require this utterly away

  3. Raymond says:

    I read a lot of interesting content here.
    Probably you spend a lot of time writing, i know how to save you a lot of work, there is an online tool that creates high quality, google friendly posts in seconds, just type in google – laranitas free content source

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>